C. Fleck, M. Schwertfeger, P. M. Taylor (2003). Regulation of renal amino acid (AA) transport
by hormones, drugs and xenobiotics—a review. Amino Acids 24: 347–374.
N. J. Gittoes, J. A. Franklin (1998). Hyperthyroidism: current treatment guidelines. Drugs 55: 543.
F. S. Greenspan (1991). Thyroid disease. Med. Clin. North Am. 75 :1.
R. S. Lindsay, A. D. Toft (1997). Hypothyroidism. Lancet 349: 413.
M. I. Surks, R. Sievert (1995). Drugs and thyroid function. N. Engl. J. Med. 333: 1688.
B. D. Weintraub, M. S. Szkunlinski (1999). Development and in vitro characterization of human
recombinant thyrotropin. Thyroid 9: 447.
Insulin and Glucagon
A. D. Cherrington (1999). Banting Lecture 1997. Control of glucose uptake and release by the
liver in vivo. Diabetes 48: 1198.
M. P. Czech (1985). The nature and regulation of the insulin receptor: structure and function.
Annu. Rev. Physiol. 47: 357–391.
S. Gammeltoft (1984). Insulin receptors: binding kinetics and structure–function relationship of
insulin.Physiol Rev. 64: 1321–1378.
V. J. Hruby, J.-M. Ahn, D. Trivedi (2001). The design and biological activities of glucagon
agonists and antagonists, and their use in examining the mechanisms of glucose action. Curr.
Med. Chem. Immunol. Endocr. Metabol. Agents 1: 199–215.
R. Iyengar (1986). Structural characterization of the glucagon receptor. In: N. Kraus-Friedman
(Ed.).Hormonal Control of Gluconeogenesis, vol. 2. Boca Raton: CRC Press, pp. 21–34.
P. F. Kador, J. H. Kinoshita, N. E. Sharpless (1985). Aldose-reductase inhibitors: a potential new
class of agents for the pharmacological control of certain diabetic complications. J. Med.
Chem. 28: 841–849.
W. L. Lee, B. Zinman (1998). From insulin to insulin analogs: progress in the treatment of type
1 diabetes. Diabetes Rev. 6: 73.
A. Ling (2002). Small-molecule glucagon receptor antagonists. Drugs Fut. 27: 987–993.
C. A. Lipinski, N. J. Hutson (1984). Aldose-reductase inhibitors as a new approach to the treat-
ment of diabetic complications. Annu.Rep. Med. Chem. 19: 169–177.
M. E. V. Mora, A. Scarfone, M. Calvani, A. V. Greco, G. Mingrone (2003). Insulin clearance in
obesity. J. Am. Coll. Nutr. 22: 487–493.
E. van Obberghen, S. Gammeltoft (1986). Insulin receptors: structure and function. Experientia
42 : 727–734.
L. Pirola, A. M. Johnston, E. van Obberghen (2003). Modulators of insulin action and their role
in insulin resistance. Int. J. Obes. 27(suppl. 3): S61–S64.
C. R. Rasmussen, B. E. Maryanoff, G. F. Tutwiler (1981). Diabetes mellitus. Annu.Rep. Med.
Chem. 16: 173–188.
A. R. Saltiel, J. A. Fox, P. Sherline, P. Cuatrecasas (1986). Insulin-stimulated hydrolysis of a
novel glycolipid generates modulators of cAMP phosphodiesterase. Science 233: 967–972.
P. R. Shepherd, B. B. Kahn (1999). Glucose transporters and insulin action—implications for
insulin resistance and diabetes mellitus. N. Eng. J. Med. 341: 248.
Hormones and Hypertension
J. M. Connell (1986). Essential hypertension: rational pharmacotherapy. Trends Pharmacol.Sci.
7 : 412-419.
D. W. Cushman, M. A. Ondetti (1980). Control of blood pressure by angiotensin blockage.
Trends Pharmacol. Sci. 1 : 260–263.
384 MEDICINAL CHEMISTRY